# Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma

> **NCT04895046** · PHASE2 · WITHDRAWN · sponsor: **Walid Shaib, MD**

## Conditions studied

- HRD
- Cholangiocarcinoma
- Metastatic Cancer

## Interventions

- **DRUG:** Niraparib
- **DRUG:** Dostarlimab
- **DRUG:** Dostarlimab

## Key facts

- **NCT ID:** NCT04895046
- **Lead sponsor:** Walid Shaib, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-10-11
- **Primary completion:** 2022-09
- **Final completion:** 2023-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funder decision
- **Last updated:** 2022-06-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04895046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04895046, "Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04895046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*